Kymera Therapeutics, Inc.
KYMR
$61.00
$1.111.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.76M | 11.48M | 22.10M | 7.39M | 3.74M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.76M | 11.48M | 22.10M | 7.39M | 3.74M |
| Cost of Revenue | 74.09M | 78.39M | 80.26M | 71.82M | 60.41M |
| Gross Profit | -71.33M | -66.91M | -58.16M | -64.42M | -56.67M |
| SG&A Expenses | 17.34M | 17.65M | 16.27M | 16.33M | 15.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 91.43M | 96.03M | 96.53M | 88.15M | 75.87M |
| Operating Income | -88.67M | -84.56M | -74.43M | -80.76M | -72.12M |
| Income Before Tax | -82.18M | -76.61M | -65.58M | -70.75M | -62.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.18M | -76.61M | -65.58M | -70.75M | -62.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.18M | -76.61M | -65.58M | -70.75M | -62.49M |
| EBIT | -88.67M | -84.56M | -74.43M | -80.76M | -72.12M |
| EBITDA | -85.82M | -83.17M | -72.38M | -80.17M | -69.34M |
| EPS Basic | -0.94 | -0.95 | -0.82 | -0.88 | -0.82 |
| Normalized Basic EPS | -0.56 | -0.60 | -0.51 | -0.55 | -0.51 |
| EPS Diluted | -0.94 | -0.95 | -0.82 | -0.88 | -0.82 |
| Normalized Diluted EPS | -0.56 | -0.60 | -0.51 | -0.55 | -0.51 |
| Average Basic Shares Outstanding | 87.30M | 80.45M | 80.15M | 79.99M | 76.13M |
| Average Diluted Shares Outstanding | 87.30M | 80.45M | 80.15M | 79.99M | 76.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |